Featured
Iron Safety Hits AMAG Pharmaceuticals
Shares of AMAG Pharmaceuticals, Inc. (AMAG) traded as low as $37.70 today, down nearly 17% from the prior close of $45.25 due to purported safety concerns regarding Feraheme® [ferumoxytol], the company’s marketed product for the treatment of iron deficiency anemia [IDA] in adult patients with chronic kidney disease [CKD]. Despite the use of recombinant... Read more of this article
More Posts From Featured
Articles
Biotech Deal Activity Declines…The Pause that Refreshes?
* MD Becker Partners reporting live from the JP Morgan Healthcare Conference This...
2009: Biotech’s Stealth Small Cap Rally
On the heels of the Dow Jones Industrial Average (DJIA) logging its worst annual...
Graft Versus Host Disease: Failures and Future Opportunities
In September 2009, Osiris Therapeutics, Inc. (OSIR) reported preliminary results...
Buyout Buzz at ASH Hematology Confab
Scientific and medical advances weren’t the only topic of discussion at the 51st...
More Posts From Articles
Opinion Editorials (OpEd)
Innovative New Medicines are Key to Economic Growth
The life sciences industry [herein includes pharmaceutical, biotechnology, diagnostic...
Bridging the Gap – Translating NIH Funding in a Post-Stimulus Economy
On February 17, 2009, President Obama announced as part of the 2009 stimulus bill,...
Bailout for Banks and Auto Industry…What about Biotechnology?
As the CEO of a few small, publicly-traded biotechnology companies during the past...
More Posts From Opinion Editorials (OpEd)
